報價延遲最少15分鐘:2026/06/03 08:31 EDT
盤前時段
|
||||
|
82.06 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
81.57
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.23/-5.32
|
|
企業價值
4.89B
|
| 資產負債 |
|
每股賬面淨值
21.98
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
2.04M
|
|
每股收益
0.12
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic. |
